361 related articles for article (PubMed ID: 27377542)
1. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial.
Huang G; Wharton W; Bhasin S; Harman SM; Pencina KM; Tsitouras P; Li Z; Hally KA; Asthana S; Storer TW; Basaria S
Lancet Diabetes Endocrinol; 2016 Aug; 4(8):657-665. PubMed ID: 27377542
[TBL] [Abstract][Full Text] [Related]
2. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.
Resnick SM; Matsumoto AM; Stephens-Shields AJ; Ellenberg SS; Gill TM; Shumaker SA; Pleasants DD; Barrett-Connor E; Bhasin S; Cauley JA; Cella D; Crandall JP; Cunningham GR; Ensrud KE; Farrar JT; Lewis CE; Molitch ME; Pahor M; Swerdloff RS; Cifelli D; Anton S; Basaria S; Diem SJ; Wang C; Hou X; Snyder PJ
JAMA; 2017 Feb; 317(7):717-727. PubMed ID: 28241356
[TBL] [Abstract][Full Text] [Related]
3. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial.
Basaria S; Harman SM; Travison TG; Hodis H; Tsitouras P; Budoff M; Pencina KM; Vita J; Dzekov C; Mazer NA; Coviello AD; Knapp PE; Hally K; Pinjic E; Yan M; Storer TW; Bhasin S
JAMA; 2015 Aug; 314(6):570-81. PubMed ID: 26262795
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.
Andrieu S; Guyonnet S; Coley N; Cantet C; Bonnefoy M; Bordes S; Bories L; Cufi MN; Dantoine T; Dartigues JF; Desclaux F; Gabelle A; Gasnier Y; Pesce A; Sudres K; Touchon J; Robert P; Rouaud O; Legrand P; Payoux P; Caubere JP; Weiner M; Carrié I; Ousset PJ; Vellas B;
Lancet Neurol; 2017 May; 16(5):377-389. PubMed ID: 28359749
[TBL] [Abstract][Full Text] [Related]
5. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
Wittert G; Bracken K; Robledo KP; Grossmann M; Yeap BB; Handelsman DJ; Stuckey B; Conway A; Inder W; McLachlan R; Allan C; Jesudason D; Fui MNT; Hague W; Jenkins A; Daniel M; Gebski V; Keech A
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):32-45. PubMed ID: 33338415
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Huntington Study Group Reach2HD Investigators
Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
[TBL] [Abstract][Full Text] [Related]
7. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
[TBL] [Abstract][Full Text] [Related]
8. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials.
Bhasin S; Ellenberg SS; Storer TW; Basaria S; Pahor M; Stephens-Shields AJ; Cauley JA; Ensrud KE; Farrar JT; Cella D; Matsumoto AM; Cunningham GR; Swerdloff RS; Wang C; Lewis CE; Molitch ME; Barrett-Connor E; Crandall JP; Hou X; Preston P; Cifelli D; Snyder PJ; Gill TM
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):879-890. PubMed ID: 30366567
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.
Costa ACS; Brandão AC; Boada R; Barrionuevo VL; Taylor HG; Roth E; Stasko MR; Johnson MW; Assir FF; Roberto MP; Salmona P; Abreu-Silveira G; Bederman I; Prendergast E; Hüls A; Abrishamcar S; Mustacchi Z; Scheidemantel T; Roizen NJ; Ruedrich S
Lancet Neurol; 2022 Jan; 21(1):31-41. PubMed ID: 34942135
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
11. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
Ngandu T; Lehtisalo J; Solomon A; Levälahti E; Ahtiluoto S; Antikainen R; Bäckman L; Hänninen T; Jula A; Laatikainen T; Lindström J; Mangialasche F; Paajanen T; Pajala S; Peltonen M; Rauramaa R; Stigsdotter-Neely A; Strandberg T; Tuomilehto J; Soininen H; Kivipelto M
Lancet; 2015 Jun; 385(9984):2255-63. PubMed ID: 25771249
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
[TBL] [Abstract][Full Text] [Related]
13. Effects of a Six-Month Multi-Ingredient Nutrition Supplement Intervention of Omega-3 Polyunsaturated Fatty Acids, vitamin D, Resveratrol, and Whey Protein on Cognitive Function in Older Adults: A Randomised, Double-Blind, Controlled Trial.
Moran C; Scotto di Palumbo A; Bramham J; Moran A; Rooney B; De Vito G; Egan B
J Prev Alzheimers Dis; 2018; 5(3):175-183. PubMed ID: 29972210
[TBL] [Abstract][Full Text] [Related]
14. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.
Emmelot-Vonk MH; Verhaar HJ; Nakhai Pour HR; Aleman A; Lock TM; Bosch JL; Grobbee DE; van der Schouw YT
JAMA; 2008 Jan; 299(1):39-52. PubMed ID: 18167405
[TBL] [Abstract][Full Text] [Related]
15. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial.
Spitzer M; Basaria S; Travison TG; Davda MN; Paley A; Cohen B; Mazer NA; Knapp PE; Hanka S; Lakshman KM; Ulloor J; Zhang A; Orwoll K; Eder R; Collins L; Mohammed N; Rosen RC; DeRogatis L; Bhasin S
Ann Intern Med; 2012 Nov; 157(10):681-91. PubMed ID: 23165659
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
[TBL] [Abstract][Full Text] [Related]
17. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
18. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
[TBL] [Abstract][Full Text] [Related]
19. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Jenkins VA; Ambroisine LM; Atkins L; Cuzick J; Howell A; Fallowfield LJ
Lancet Oncol; 2008 Oct; 9(10):953-61. PubMed ID: 18768369
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
